A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson’s Disease in Participants With Leucine‐Rich Repeat Kinase 2 Mutation-Reference-Cited by-同舟云学术

A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson’s Disease in Participants With Leucine‐Rich Repeat Kinase 2 Mutation

Published:2021-06-12 Issue:2 Volume:110 Page:508-518
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Ahamadi Malidi¹,Mehrotra Nitin¹,Hanan Nathan²,Lai Yee Ka¹,Gheyas Ferdous¹,Anton Judith¹,Bani Massimo³,Boroojerdi Babak³,Smit Hans³,Weidemann Jonas⁴,Macha Sreeraj⁵,Thuillier Vincent⁵,Chen Chao⁶,Yang Minhua⁷,Williams‐Gray Caroline H.⁸,Stebbins Glenn T.⁹,Pagano Gennaro¹⁰,Hang Yaming¹¹,Marek Kenneth¹²,Venuto Charles S.¹³,Javidnia Monica¹³,Dexter David¹⁴,Pedata Anne²,Stafford Bob²,Akalu Mussie²,Stephenson Diane²,Romero Klaus²,Sinha Vikram¹,

Affiliation:

1. Merck & Co., Inc. Kenilworth New Jersey USA

2. Critical Path Institute Tucson Arizona USA

3. Union Chimique Belge Brussels Belgium

4. Lundbeck Copenhagen Denmark

5. Sanofi Chilly‐Mazarin France

6. GlaxoSmithKline Brentford UK

7. Biogen Cambridge Massachusetts USA

8. Department of Clinical Neurosciences University Cambridge Cambridge UK

9. Rush University Chicago Illinois USA

10. Neuroscience and Rare Disease Discovery and Translational Area Roche Pharma Research and Early Development F. Hoffmann‐La Roche Ltd Basel Switzerland

11. Takeda Cambridge Massachusetts USA

12. Institute of Neurodegenerative Diseases New Haven Connecticut USA

13. University of Rochester Rochester New York USA

14. Parkinson’s UK London UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2277

Reference44 articles.

1. Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016